Pyroidno-4-iodotamoxifen (idoxifene) is a new non-steroidal antioestrogen currently undergoig phase I clnical evaluation. Using idoxifene and tamoxifen and two additional analogues of tamoxifen (3-hydroxytamoxifen and 4-iodotamoxifen) and the imidazole-based calmoduin inhibitor, anmidazolim, a strong positive correlation (r2>0.95) was observed between cytotoxicity and inhibition of cahodulindependent cyclic AMP phosphodiesterase (e.g. mean IC", across four human ovaran carcnoma cell lnes of 4.5 pm for idoxifene and 6.3 pM for tamoxifen). Using two parent human ovarian carcinoma cel lines (41M and CHI; both oestrogen receptor negative) in which acquired resstance to doxorubicin or cisplatin has been generated, we have determined the ability of idoxifene to overcme resistance in these lnes. At a non-toxic concentration of 2 P, idoxifene appeared at kast as effective as the clnically used multidrug resistance modis vpamil and tamoxifen in overcoming doxorubicin resistance in two acquired resistant cell lnes shown to overexres the P-170 efflux glycoprotein. Non-cross-resistance between ciplatin and idoxifene was observed in two acquired resstant cell lnes possessing contrasting nsm of resistance to cisplatin (41McisR6 reduced drug tansport and CHIcisR6 resistance mediated at the level of DNA). In one of four cell lines (CHI), synergism between idoxifene and cispLain was observed by median effect analysis. However, with the 41M and its 6-fold cisplatin-resistant variant, antagonism was observed. These observations made by median effect analysis appeared to be unrelated to platinum uptake or removal of platinum-induced DNA interstrand cross-nk s. These in vitro data suggest that idoxifene may be usefully combined with doxorubicin in the cinical setting, but caution should be exercised in combining it with cisplatin in the treatment of certain tumours.
The clinical effectiveness of the widely used anti-cancer drugs, cisplatin [cis-diamminedichloroplatinum (II)] and doxorubicin, is commonly limited by tumour resistance, either present at the outset or acquired during chemotherapy. Resistance to cisplatin has been shown to be mediated through one or more of reduced drug influx, increased intracellular detoxification by glutathione and/or metallothioneins or increased removal of DNA-platinum adducts (see McKeage & Kelland, 1993 , for a review). In contrast, resistance to doxorubicin is commonly attributable to enhancd drug efflux through either the P-170 transmembrane glycoprotein (Kartner et al., 1983) al., 1992, 1993a ) and a human ovarian carcinoma and small-cell lung cancer cell line (McClay et al., 1993b) . Synergisi antiproliferative activity of tamoxifen and cisplatin has also been shown using a primary ovarian tumour (Scambia et al., 1992) . At present, the underlying mechanism(s) responsible for the synergy is unclear. As well as its effects on the oestrogen receptor, tamoxifen has been shown to exert inhibitory effects on calmodulin (Lam, 1984) and protein kinase C (O'Brian et al., 1985) . Whether these effects contribute to the therapeutic utility of taxoxifen is uncertain, although the drug has been reported to produce some responses in a small number of oestrogen receptor-negative tumours (Breast Cancer Trials Committee, 1987) . Interestingly, the calmodulin antagonist W-7 [(N-6aminohexyl)-5-chloro-l-naphthalenesulphonamide] has been shown to increase cisplatin uptake in cisplatin-resistant cells (Kikuchi et al., 1990) , and another calmodulin inhibitor, trifluoperazine, has been shown to potentiate cisplatin cytotoxicity (Perez et al., 1992a) .
Pyrrolidino-4-iodotamoxifen (idoxifene) is one of a series of recently synthesised 4-substituted analogues of tamoxifen (McCague et al., 1989) . It has also been shown that idoxifene has a greater ability to inhibit calmodulin-dependent cyclic AMP phosphodiesterase than tamoxifen itself (IC50 of 1.4 1LM vs 6.75 jpM for tamoxifen) (Rowlands et al., 1990) . Idoxifene is currently undergoing phase I clinical evaluation in advanced breast cancer (Quigley et al., 1993) . Figure 1 . Idoxifene and 4-iodotamoxifen were synthesised according to McCague et al. (1989) , and 3-hydroxytamoxifen, also in clinical evaluation under the name of droloxifene (Bruning, 1992) , by Foster et al. (1985) (droloxifene) final concentration of ethanol (0.5%) in growth medium had no inhibitory effect on cell growth. Cisplatin was dissolved in 0.9% saline at 500 gm.
The cytotoxicities of the drugs were assessed using the SRB assay, and this was performed as described previously (Kelland et al., 1992b The cytotoxicity data of idoxifene, cisplatin and combinations of these drugs in constant molar ratios were analysed by median effect analysis (Chou & Talalay, 1984 verapamil and sulphorhodamine B (SRB) were obtained from Sigma.
Cell lines
Two 'parent' human ovarian carcinoma cell lines (41M and CHI) were used in this study-, their biological properties have been described previously (Hills et al., 1989) . Both cell lnes were essentially negative for the expron of oestrogen receptors (possing <10fmolmg-' cytosol protein) (Hills et al., 1989) . Cisplatin acquired rstant vanants to these cell lines were generated as described previously (Kelland et al., 1992a Determination of DNA interstrand cross-link repair by alkalue ehution DNA interstrand cross-linking was assessed by alkalie elution, as described by Kelland et al. (1992a) . Briefly, after 2 h exposure to cisplatin, cells were washed with PBS at 37C and further incubated with idoxifene (2 pM) for 0, 5 and 24 h.
For cells without idoxifene, medium was added. Crosslinking index was calculated using the following formula as described previously (Roberts & Friedlos, 1987) :
Cross-linking index = (V1 ro-1) I xP where r and ro are the fractions of`4C-labelled DNA for treated versus control cells remaining on the filter when 50% of 3H-labelled DNA is retained on the filter and P is the rad equivalent (517). Results were then expressed as the crosslinkling index versus the time when cisplatin was removed and idoxifene was introduced during the repair period.
Statistical analysis
Where appropriate, statistical significe was tested using a two-tailed Student's f-test; a P-value <0.05 was considered significant.
Reis
Initially, the cytotoxicity of tamoxifen, three analogues (3-hydroxytamoxifen, 4-iodotamoxifen and idoxifene) and the calmodulin antagonist camidazolum (R24571) was determined against four human ovarian carcinoma cell lines, 41M and CHI and their acquired cisplatin-resistant variants 41McisR6 and CHIcisR6. The results (Figure 2a for 41M lnes and Figure 2b for CHI lines) showed a strong correlation between the inhibition of calmodulin-dependent cyclic AMP phosphodiestase [vahls taken from previous determinations (Rowlands et al., 1990) In preliminary experiments, the highest non-toxic concentration of the resistance modifiers (<10% cell kill in any one cell line; continuous drug exposure) was determined as 6 9AM for verapamiL 4 JM for tamoxifen and 2 M for idoxifene.
These concentrations were then used in combination with doxorubicin. The results are shown in Table I . While none of the modifiers exerted any marked effect on the cytotoxicity of doxorubicin to the parent cell lnes, all reduced the kvel of doxorubicin reance in the acquired resstant ines.
Notably, idoxifene appeared at last as effective as the cliniall used mutdrug reistance modfirs verapamil and tamoxifen m overcoming doxorubicin reistance in these two cel line models.
Activity of idoxifene against acquired cisplatin-resistant cell lines
Cross-resistance profiles for both the 41M and CHI pairs of lnes to idoxifene, tamoxifen, 3-hydroxytamoxifen, 4-iodotamoxifen and the potent imidazole-based cahmodulin inhibitor, camnidazolium, showed that, whereas both of the acquired resistat cell lines exhibited around 6-fold rsistance to cisplatin, no cross-resistance (istance factor <1) was observed to all of the tamoxifen analogues and cabmidazolium.
In view of previously reported synergistic effects between cisplatin and tamoxifen (McClay et al., 1992 (McClay et al., , 1993a we have ivestigated the ability of idoxifene to potentiate the cytotoxicity of cisplatin in these two paired cel lines by two independent methods. Ftrsdy, cells were exposed concomitantly (continuous exposure) to cisplatin at various concentrations and idoxifene at a fixed, highest non-toxic concentration (2pM) of idoxifene. (Chou & Talalay, 1984) . The results are shown in Table HI . Contrasting effects were observed in the two pairs of lnes. While the drug combination was antagonistic (combination index > 1) in the 41M and 41McisR6 cell lines, weak synergistic effects were observed with CHI. A previous study (Perez et al., 1992b) used sham combinations of cisplatin and carboplatin; CI values at Fa = 0.5 ranged from 0.953 ± 0.289 to 0.935 ± 0.271. Therefore, the combination in the CHlcisR6 line is additive.
We have begun to investigate the possible mechanistic basis of the contrasting median effect analysis data for the two pairs of cell lines. Figure 4 shows platinum accumulation data for 4lMcisR6 (Figure 4a ) and CHlcisR6 (Figure 4b) following a 2 h exposure of cells to differing concentrations of cisplatin either alone or in the presence of 2 FM idoxifene. Although reduced platinum uptake has previously been shown to be a major contributing factor to the acquired rsistance observed in 4lMcisR6 cells (Loh et al., 1992) and marked antagonism (Table Ill) platinum accumulation in the pirsence of idoxifene. Similarly, no difference in uptake was observed in the CHlcisR6 cell line.
Our previous findings have shown that acquired istance to cisplatin in the CHI/CHlcisR pair of lines is meiated at the level of DNA, similar kvels of total platinum being bound to DNA in the two cell ines following equiolar concentrations of cisplatin (Kelland et al., 1992a) . Figure 5 shows (Hait, 1987) , futher variation of the alkylaminoethoxy side chain of tamoxifen to obtain even greater inhibition of calmodulin is in progress. Previous studis with the same series of compounds have shown a similar correlation between calmodulin inhibition and cytotoxicty for oestrogen receptor-positive MCF-7 human breast cancer cells but no such correlation for murine L1210 or rat Walker cells (Rowlands et al., 1990) .
Tamoxifen has proven to be one of a number of diverse agents capable of reversing P-170 glycoprotein-mediated multidrug reistance (Ramu et al., 1984; Beck, 1991) . One of the most studied agents in this context in the cinic has been the calcium channel blocker verapamil (Beck, 1991 al., 1992, 1993a) .
In addition to effects on oestrogen receptors, tamoxifen has also been reported to exert other effects, notably on calmodulin (Lam, 1984) and protein kinase C (O'Brian et al., 1985) . Moreover, calmodulin inhibitors, W-7 [(N-6amino-hexyl)-5-chloro-1-naphthalenesulphonamideI and the clinically used antipsychotic agent, trifluoperazine, have both been shown to potentiate the cytotoxic effects of cisplatin in vitro (Kikuhi et al., 1990; Perez et al., 1992a) . In the trifluoperazine plus cisplatin study, synergy was observed in four of six cell lines by median effect analysis, while clear antagonism was apparent in the remaining cell lines (Pere et al., 1992a) . Intriguingly, with the W-7 study, potentiation appeared to be mediated through enhanced platinum uptake, while with trifluoperazne a mechanism involving inhibition of the incision step of DNA repair was proposed. In our studies, however, the disparate results obtained by median effect analysis did not appear to be related to either platinum uptake or repair of platinum-DNA adducts (although it should be noted that the DNA interstrand cross-links measured by alklin elution only represent about 2% of the total platinum-DNA adducts induced by cisplatin). Furthermore, the synergy observed in the T-289 melanoma cell line did not appear to be related to effects on calmodulin (or protein kinase C) (McClay et al., 1993a) . Nevertheless, as idoxifene is a more effective inhibitor of calmodulin than tamoxifen (Rowlands et al., 1990) 
